louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06221566: Effectiveness of Muscle Energy Technique (MET) Versus Stretching Exercises In Acute And Subacute Postural Neck Pain
Official title: Effectiveness of Muscle Energy Technique (MET) Versus Stretching Exercises In Acute And Subacute Postural Neck Pain. A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Pain
Keywords: Proprioceptive Neuromuscular Facilitation (PNF)
Static stretching exercises
Visual analog scale
Lead sponsor: Dow University of Health Sciences
Sponsor class: OTHER
First posted: 2024-01-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: TREATMENT

Brief summary: This study will provide better evidence that which technique is more effective in acute and subacute postural neck pain. To find out the effectiveness of Muscle energy technique (MET) and stretching exercises in acute and subacute postural neck pain.

Detailed description: Study Design: Randomized Controlled Trial Study Setting: The study will be conducted at the Institute of Physical Medicine and Rehabilitation, Dow University of Health Sciences, Karachi, Pakistan.

Intervention: This study will identify effects of two intervention approaches. The Experimental group consists of muscle energy technique (MET) for upper trapezius and levetor scapulae muscle of neck. The Control group will receive a stretching exercises program for upper trapezius and levetor scapulae muscle of neck.

Eligibility criteria: Inclusion Criteria:

* Targeted population: Students of MBBS, Pharmacy and Doctor of physical therapy.
* Age between 18 and 30 years
* Patient having acute or subacute postural neck pain
* Acute postural neck pain should not last longer than 4weeks
* Subacute postural neck pain should not last longer than 4-12 weeks.

Exclusion Criteria:

* Cervicogenic headaches
* Musculoskeletal disorders involve the nerve root compression, i.e.; (Intervertebral disc dysfunction and derangement syndrome)
* Whiplash associated disorders
* Fibromyalgia
* Spinal cord injury
* Neurological disorders i.e.; (Multiple sclerosis, Young Parkinsonism etc.)

Primary outcomes:
measure: Visual Analog Scale
timeFrame: 03 weeks (1st, 8th, 15th, 21st day)
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Nida Naqi
state: Sindh
Study officials:
affiliation: Dow University of Health Sciences
name: NIDA NAQI, MSAPT
role: PRINCIPAL_INVESTIGATOR
References:
citation: Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978 Aug;37(4):378-81. doi: 10.1136/ard.37.4.378.
citation: Hoy DG, Protani M, De R, Buchbinder R. The epidemiology of neck pain. Best Pract Res Clin Rheumatol. 2010 Dec;24(6):783-92. doi: 10.1016/j.berh.2011.01.019.
Clinical trial NCT03059966: Evaluation of the Inflammatory and Healing Profile After Root Coverage With Emdogain®
Official title: Evaluation of the Inflammatory and Healing Profile After Root Coverage With Emdogain®
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Gingival Recession
Lead sponsor: Rio de Janeiro State University
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 16
Sex: ALL
Minimum age (years): 29
Maximum age (years): 53
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was the evaluation of inflammatory and healing profile after root coverage using of Enamel Matrix Derivative. 16 volunteers were selected and submitted to root coverage surgery with subepithelial connective tissue graft, with and without enamel matrix derivative. The patient screening was based in the following inclusion criteria: bilateral recessions in maxillary anterior homologous teeth with aesthetical complaining ou hypersensitivity, non-smokers, healthy and no use of any medication that compromises periodontal health or healing. The split-mouth randomized model was followed in relation to test and control sites. The following clinical parameters were analyzed at baseline and 6-month post-surgery: recession height, recession width, width of keratinized tissue, probing depth, clinical attachment level, and gingival thickness. In addition to the surgical analysis, evaluations of the following inflammatory markers were performed: IL-1β, IL -1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12, IL-13, IL-15, IL-17, EOTAXIN, FGF, GCSF, GMCSF, IFN-y, IP-10, MCP-1, MIP 1a, PDGF-bb, MIP 1b, RANTES, TNF-α e VEGF. These evaluations were performed at baseline, 7 and 14 days after surgery.


Eligibility criteria: Inclusion Criteria:

* Bilateral gingival recessions in homologous teeth

Exclusion Criteria:

* Smokers;
* Systemic diseases;
* Drugs affecting periodontal health/healing.

Primary outcomes:
measure: Post-surgical pain
timeFrame: 7 days after surgery
measure: Root Coverage Score
timeFrame: 180 days after surgery
measure: Post-surgical Clinical Analysis
timeFrame: 180 days after surgery
measure: Changes in Gingival Fluid Biomarkers
timeFrame: Baseline, 7 and 14 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03925766: Laparoscopy-Assisted Transgastric ERCP
Official title: Laparoscopy-Assisted Transgastric Endoscopic Retrograde Cholangiopancreatography for Choledocholithiasis After Roux-en-Y Gastric Bypass
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Biliary Obstruction
Keywords: biliary disease
gallstones
obesity
Lead sponsor: Tecnologico de Monterrey
Sponsor class: OTHER
First posted: 2019-04-24
Enrollment: 1
Sex: MALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with altered Roux en Y Gastric Bypass anatomy

Brief summary: We describe a case of a 57-year-old patient with altered RYGB anatomy, who underwent a laparoscopic cholecystectomy with a intra-operative cholangiogram showing a stone on the common bile duct. A laparoscopic assisted trans-gastric ERCP was successfully performed. The presentation of the case is presented as well a review of the literature.

Detailed description: The exclusion of the stomach after Roux-en-Y-Gastric bypass (RYGB) makes access to the biliary tree very challenging for the surgeon or the endoscopist. There are different techniques described to overcome this downside, being laparoscopic assisted trans-gastric endoscopic retrograde cholangiopancreatography (ERCP) approach an outstanding method to access the remnant stomach for reaching the duodenal papilla, with a high rate of success reported. We describe a case of a 57-year-old patient with altered RYGB anatomy, who underwent a laparoscopic cholecystectomy with a intra-operative cholangiogram showing a stone on the common bile duct. A laparoscopic assisted trans-gastric ERCP was successfully performed, introducing the duodenoscope through a gastrostomy without the need of an intra-gastric trocar. The patient evolved favorably and was discharged on his second postoperative day without complications.

Eligibility criteria: Inclusion Criteria:

* Patient with altered Roux en Y Gastric Bypass anatomy

Exclusion Criteria:

* Patients without Roux en Y Gastric Bypass anatomy

Primary outcomes:
measure: Proof the efficacy of laparoscopic assisted transgastric endoscopic retrograde cholangiopancreatography
timeFrame: April 2019
Secondary outcomes:
Other outcomes:
Locations:
city: Monterrey
country: Mexico
facility: Escuela Nacional de Medicina, Tecnologico de Monterrey
state: Nuevo Leon
Study officials:
References:
Clinical trial NCT01091766: Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine
Official title: Sensitivity of Electrocardiogram on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine: a Study in Children of Different Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anaesthesia
Toxicity
Keywords: local anaesthetics toxicity
heart arrhythmia
heart rate
heart conduction
regional anaesthesia
paediatric anaesthesia
cardio-vascular system
prevention
Lead sponsor: University Children's Hospital, Zurich
Sponsor class: OTHER
First posted: 2010-03-24
Enrollment: 150
Sex: ALL
Minimum age (years): 1
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this prospective randomised study is to investigate electrocardiographic alterations after intravascular injection of three different test solutions of bupivacaine and epinephrine in anaesthetised children up to 16 years of age.


Eligibility criteria: Inclusion Criteria:

* Age 0 to 16
* healthy
* parental consent

Exclusion Criteria:

* ASA \>1
* allergy against local anaesthetics

Primary outcomes:
measure: T-wave elevation in the ECG after intravenous administration of the test solution
timeFrame: 2 minutes
Secondary outcomes:
measure: Alteration in heart rate caused by intravenous injection of the test solution
timeFrame: 2 minutes
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Children's Hospital, Anesthesiology
Study officials:
affiliation: University Childrens Hospital Zurich, Anesthesiology
name: Markus Weiss, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mauch J, Kutter AP, Madjdpour C, Koepfer N, Frotzler A, Bettschart-Wolfensberger R, Weiss M. Electrocardiographic alterations during intravascular application of three different test doses of bupivacaine and epinephrine: experimental study in neonatal pigs. Br J Anaesth. 2010 Jan;104(1):94-7. doi: 10.1093/bja/aep313.
Clinical trial NCT01991366: Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Official title: Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: ST-elevation Myocardial Infarction
Acute Myocardial Infarction
Keywords: Major adverse microvascular integrity
all cause mortality
Q Wave MI
Lead sponsor: Medstar Health Research Institute
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who underwent primary Percutaneous Coronary Intervention at Washington Hospital Center since September 2000 and received eptifibatide pre-or during PCI or have received no eptifibatide.

Brief summary: The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction in a large tertiary referral center.

It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is superior to unfractionated heparin alone or bivalirudin alone. Additionally, after propensity matching this superiority remains.

Detailed description: This is a retrospective, observational, data analysis of approximately 800 patients who underwent primary Percutaneous Coronary Intervention at our institution since September 2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to Percutaneous Coronary Intervention will be excluded.

This analysis is estimated to take 1-2 months.

Eligibility criteria: Inclusion Criteria:

* Underwent Percutaneous Coronary Intervention at Washington Hospital Center since September 2000
* Either received eptifibatide pre-or during PCI or have received no eptifibatide.

Exclusion Criteria:

* Patients who received a thrombolytic prior to Percutaneous Coronary Intervention.

Primary outcomes:
measure: All-cause mortality and composite or Q-wave myocardial infarction
timeFrame: Chart review 6 months after PCI
Secondary outcomes:
measure: TIMI major bleeding
timeFrame: During hospital stay; average stay is less than 48 hours
Other outcomes:
Locations:
city: Washington
country: United States
facility: Washington Hospital Center
state: District of Columbia
Study officials:
affiliation: Medstar Health Research Institute
name: Ron Waksman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05397366: Comparison of TSTVs NT Along With Conventional Therapy for Upper Limb Motor Function Among Chronic Stroke Patients
Official title: Comparison of Task Specific Training Vs Neurodevelopmental Training Along With Conventional Therapy for Upper Limb Motor Function Among Chronic Stroke Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2022-05-31
Enrollment: 74
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Comparison of Task Specific Training Vs Neurodevelopmental Training Along with Conventional Therapy for Upper Limb Motor Function Among Chronic Stroke Patients

Detailed description: To compare Task Specific Training versus Neurodevelopmental Training along with conventional therapy for upper limb motor function among chronic stroke patients.

Eligibility criteria: Inclusion Criteria:

* Chronic ischemic stroke patients( after 3 months of stroke ).(41)
* Patients from both gender.(42)
* Patients of around age of 45-65.(43)
* Patient with limb spasticity equal to 2 or less than 2 on modified ash worth scale.(44)
* Patient with good cognitive function minimum 20 or more on Mini Mental State Examination (MMSE).(45)

Exclusion Criteria:

* Patients with history of the recurrent stroke.(41)
* Patient with fracture or dislocation of upper limb.(46)
* Patient with any peripheral vascular disease (47)
* Patient with any comorbid neurological disease like Parkinsonism, epilepsy, multiple sclerosis and spinal cord injury.(21)
* Patient with skin discoloration, skin ulcers and skin allergy.(48)

Primary outcomes:
measure: Neurodevelopmental Training
timeFrame: 6 Months
Secondary outcomes:
measure: Task Specific Training
timeFrame: 6 Months
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Shadman Medical Centre Chaudhry Muhammad Akram Teaching and Research Hospital University of Lahore Teaching Hospital Services Hospital Lahore General Hospital Bashir Neuro Supine Institute
Study officials:
References:
Clinical trial NCT00237926: Comparing Aerobic to Resistance Training in Recovery From Cancer
Official title: Comparing Aerobic to Resistance Training in Recovery From Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neoplasms
Keywords: Sleep
Fatigue
Exercise tolerance
Quality of life
Health status
Lead sponsor: Brooke Army Medical Center
Sponsor class: FED
First posted: 2005-10-13
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to compare the health outcomes of a 12-week exercise program focused on aerobic training (using a treadmill) to a 12-week exercise program focused on resistance training (using Thera-Bands) in sedentary patients within 6 months of completing treatment for cancer.


Eligibility criteria: Inclusion Criteria:

* have a biopsy-proven cancer diagnosis
* be within six months of having completed chemotherapy or radiation therapy for treatment for cancer as determined by the primary physician
* be ambulatory but sedentary (i. e., has not followed an exercise regimen of a minimum of 3 times per week for at least 20 minutes each session over the previous six weeks)
* have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 asymptomatic) or 1 (symptomatic, fully ambulatory)
* be at least 18 years old
* be able to read and speak English
* have a medical statement from either the patient's primary care provider or the primary oncologist indicating that participation in the program is not medically contraindicated

Exclusion Criteria:

* following an exercise regimen a minimum of 3 times per week for at least 20 minutes each session within the previous 6 weeks
* bone or joint destruction that could be aggravated with exercise
* severe cognitive impairment identified by either the patient's medical care provider or by the study team
* neuropathy-sensory common toxicity criteria (CTC) grade 3 (sensory loss or paresthesia interfering with activities of daily living) or grade 4 (permanent sensory loss that interferes with function) peripheral neuropathy

Primary outcomes:
measure: quality of life
timeFrame: 12-weeks
Secondary outcomes:
measure: exercise tolerance
timeFrame: 12-weeks
Other outcomes:
Locations:
city: Fort Sam Houston
country: United States
facility: Brooke Army Medical Center
state: Texas
Study officials:
affiliation: United States Department of Defense
name: Stacey Young-McCaughan, RN, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02619526: Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients
Official title: Comparative Effects of Nebivolol and Carvedilol on Diastolic Function of the Left Ventricle in the Elderly Heart Failure Patients With Preserved Ejection Fraction: Study Protocol for a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Heart Failure
Lead sponsor: Dong-A University
Sponsor class: OTHER
Collaborators: name: Menarini Group
First posted: 2015-12-02
Enrollment: 62
Sex: ALL
Minimum age (years): 70
Maximum age (years): 95
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Heart failure (HF) is a common and disabling condition in the elderly. Randomized clinical trials and meta-analyses have clearly demonstrated that long-term use of β blockers improves the outcomes of patients with HF. However, limited data have been available on the treatment of HF with preserved ejection fraction (EF) in the elderly. No study has specifically compared the relative effectiveness of carvedilol and nebivolol in treating HF in old age patients with preserved EF.

Detailed description: This trial is a prospective, randomized, open-label, active controlled study designed to investigate effects of nebivolol and carvedilol on diastolic function of the left ventricle (LV) in the elderly HF patients with preserved EF.

Patients will be included in the study if they had LVEF ≥ 40%, NYHA functional class I, II or III, and clinical stability without hospital admission for HF in the preceding 3 months.

Eligibility criteria: Inclusion Criteria:

* more than 70 years
* EF ≥ 40%

Exclusion Criteria:

* contraindication to the study drug

Primary outcomes:
measure: the ratio of transmitral E velocity to early diastolic mitral annular velocity (E/E')
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Department of Internal Medicine,Dong-A University College of Medicine
Study officials:
affiliation: Dong-A University
name: Tae-Ho Park, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Park K, Park TH. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. Trials. 2016 Nov 3;17(1):530. doi: 10.1186/s13063-016-1656-y.
Clinical trial NCT04161326: Environmental Health and Myopia Prevention and Control
Official title: Environmental Health and Myopia Prevention and Control: A Longitudinal Study in China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Refractive Errors
Myopia (Disorder)
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2019-11-13
Enrollment: 100000
Sex: ALL
Minimum age (years): 6
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A prospective longitudinal cohort study of schoolchildren who studied in the 1st to 4th grades was performed.

Brief summary: Myopia is one of the major causes of low visual acuity during childhood. It is generally more prevalent in urban areas than in rural areas. Current evidence does not address our understanding of the myopia incidence and development and associated risk geographic factors, such as green spaces. Therefore, our study aimed to evaluate the association between geographic factors and myopia base on a population-based large-scaled cohort design.


Eligibility criteria: Inclusion Criteria:

* schoolchildren in the 1st to 4th grades

Exclusion Criteria:

* schoolchildren unwilling to participate

Primary outcomes:
measure: the changes of spherical equivalent refractive (RSE)
timeFrame: up to 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center, Sun Yat-sen University
state: Guangdong
Study officials:
References:
Clinical trial NCT01250626: Establish the Caring Model of Children With Chronic Kidney Disease and End-stage Renal Disease: To Set up Childhood Glomerular Filtration Rate (GFR) Formula in Taiwan
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Kidney Disease
End-Stage Renal Disease
Keywords: Inulin
childhood GFR formula
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2010-12-01
Enrollment: 80
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric OPD, age \< 18 y/o.

Brief summary: Inulin's usefulness as a diagnostic agent is based on the method of its elimination from the body. Inulin is biologically inert, unbound by plasma proteins, freely filtered at the glomerulus, and is neither reabsorbed, metabolized nor secreted by the kidneys. It is excreted almost entirely by glomerular filtration. Inulin clearance is considered to be identical to glomerular filtration rate (GFR).


Eligibility criteria: 1. Main inclusion criteria: Pediatric OPD, age \< 18 y/o.
2. Main exclusion criteria: Acute renal failure, edema, muscular dystrophy, pleural effusion, ascites, malnutrition, neurogenic bladder, heart failure and ketoacidosis. And taken cimetidine or trimethoprim, and accepted renal replacement therapy.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: